NCT05853367 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05853367
Title	Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme LLC
Indications	hepatocellular carcinoma Advanced Solid Tumor cervical cancer colorectal cancer stomach cancer endometrial cancer lung non-small cell carcinoma lung small cell carcinoma renal cell carcinoma biliary tract cancer Merkel cell carcinoma malignant mesothelioma melanoma anal squamous cell carcinoma esophageal cancer triple-negative breast cancer transitional cell carcinoma skin squamous cell carcinoma head and neck squamous cell carcinoma
Therapies	MK-0472 + MK-1084 MK-0472 MK-0472 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| ISR \| ESP \| CHE \| CAN

Additional content available in CKB BOOST